






**A Mo7-BCR-ABL****B CML #7 CD34+**untreated 5  $\mu$ M IM**C**

**Supplemental Figure 1.** Comparison of phospho-CRKL FACS, phospho-CRKL immunoblot and phosphotyrosine FACS as methods for evaluating BCR-ABL activity. **(A)** Intracellular phospho-CRKL levels were evaluated by FACS in Mo7-BCR-ABL cells treated four hours with or without 5  $\mu$ M imatinib (IM). Background signal was established in the same populations by staining with a matched isotype control. **(B)** Intracellular phospho-CRKL levels and intracellular phosphotyrosine levels were evaluated by FACS in CML CD34+ cells treated four hours with or without 5  $\mu$ M imatinib. Lysates from the same patient were evaluated by phospho-CRKL immunoblot. Total CRKL is shown as a control. **(C)** Reduction of signal upon imatinib treatment is shown for all the methodologies as a percent of untreated.